[經濟學人The Economist翻譯]A court puts decisions about gender medicine back in doctors’ hands

Source Language (English): On September 17th the Court of Appeal overturned that ruling, saying that deci­sions about whether to prescribe puberty­ blockers should be left to doctors. The rul­ing might seem of interest only to specialist medical lawyers. But the legal saga has been watched around the world, for gender dysphoria is a fast-growing diagnosis and the treatments prescribed for it are contro­versial. Referrals to the Gender Identity De­velopment Service (GIDS), England’s only dedicated youth clinic, have risen from 77 in 2009­10 to 2,383 in 2020­21. Other rich countries have seen similarly sharp rises.

Proponents describe the treatments as life­saving. Sceptics point to the lack of clinical evidence showing that they work, and to worries about severe side ­effects later in life. After the original ruling, gids suspended puberty ­blocker treatments for new patients.

Target Language: 上訴法院於同年9月17日推翻判決，並指處方青春期阻斷劑的最終決定權應交由醫生。這項判決似乎只有醫學專業律師才會感興趣，但由於患有性別焦慮的人數增長速度快，而且其處方治療方法亦備受爭議，世界各地均在關注這個議題。英國唯一青少年專門診所性別認同發展服務小組（下稱GIDS）所獲的個案轉介數量由2009至2010年度的77宗急升至2020年2021年度的2,383宗，而其他富裕國家亦有類近急劇上升/大幅上升的情況。

青春期阻斷劑的支持者形容藥物治療是他們的救命恩人，但亦有人抱存疑態度，指目前沒有足夠的醫學證據證明藥物效用，同時擔心藥物會在未來或帶來嚴重副作用。GIDS已在法院首次宣判暫停對新患者使用青春期阻斷劑。